truth about glp 1 GLP-1 Serum GLP-1 | Summary
Description
compared GLP-1RAs to seven non-GLP-1RA anti-diabetics, such as insulin and metformin, which are thought to affect the risk of CRC [149]
In clinical trials of Wegovy (FDA-approved semaglutide), participants achieved an average weight loss of approximately 15% over 68 weeks, with some participants achieving up to 20% with continued treatment and adherence, when combined with diet and exercise
For example, FDA removed tirzepatide from the drug shortage list in October 2024
The structural design is tightly linked to the therapeutic profile, enabling the next generation of innovative GLP-1 RA drugs
